newratings.com  Sep 1  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia (HeFH) patients included in the ODYSSEY clinical trial program, Praluent (alirocumab)...
Benzinga  Aug 31  Comment 
Gbola Amusa, Chardan Capital Markets' head of healthcare research, commented in a note on Monday that investors should be "more selective" in the biotech space. As such, the analyst downgraded shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN)...
Benzinga  Aug 31  Comment 
TheStreet.com  Aug 27  Comment 
NEW YORK (TheStreet) -- Shares of Regeneron Pharmaceuticals were down by 0.83% to $531 in early afternoon trading on Thursday. On Tuesday, analyst firm RBC called Regeneron Pharmaceuticals a "darling," highlighting the stock as one of 25 that...
FierceBiotech  Aug 25  Comment 
Boosted by a major new drug approval, a booming Regeneron Pharmaceuticals is swelling rapidly in size. The big biotech has added 116,200 square feet of office/lab space to its lease at the Landmark at Eastview research campus in Tarrytown, NY,...
Market Intelligence Center  Aug 12  Comment 
Regeneron Pharmaceuticals Inc (REGN) was identified by MarketIntelligenceCenter.com’s patented algorithms today after trading between $565.75 and $583.38 on Tuesday before closing at $566.99. A diagonal spread using a long position in the Jan....
Benzinga  Aug 4  Comment 
Shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) were up more than 5 percent on Tuesday after the company reported earnings of $2.89 per share on revenue of $998.62 million. The second-quarter results surpassed the Street’s consensus...
Forbes  Aug 4  Comment 
In early trading on Tuesday, shares of Regeneron Pharmaceuticals (REGN) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.3%. Year to date, Regeneron Pharmaceuticals registers a 45.0% gain.
Benzinga  Aug 4  Comment 
Lendingtree Inc (NASDAQ: TREE) shares gained 30.33 percent to reach a new 52-week high of $107.64 after the company reported better-than-expected Q2 results and raised its full-year forecast. IPC Healthcare Inc (NASDAQ: IPCM) shares climbed...
Wall Street Journal  Aug 4  Comment 
Regeneron Pharmaceuticals Inc., which recently won approval for its cholesterol drug, said profit doubled in its second quarter as sales of its eye-disease treatment surged.


Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki